Radiol Oncol 2022; 56(4): 508-514. doi: 10.2478/raon-2022-0035 508 research article Crystalloids vs. colloids for fluid optimization in patients undergoing brain tumour surgery Jasmina Markovic-Bozic1, Bozidar Visocnik1, Polona Music1, Iztok Potocnik2, Alenka Spindler Vesel1 1 Department of Anaesthesiology and Surgical Intensive Therapy, University Medical Centre Ljubljana, Ljubljana, Slovenia 2 Department of Anaesthesiology and Intensive Care, Institute of Oncology Ljubljana, Ljubljana, Slovenia Radiol Oncol 2022; 56(4): 508-514. Received 22 February 2022 Accepted 5 July 2022 Correspondence to: Assist. Prof. Jasmina Markovic-Bozic, M.D., Ph.D., Department of Anaesthesiology and Surgical Intensive Therapy, University Medical Centre Ljubljana, Zaloška 2, SI-1000 Ljubljana, Slovenia; E-mail: jasmina.markovic1@kclj.si Disclosure: No potential conflicts of interest were disclosed. This is an open access article distributed under the terms of the CC-BY license (https://creativecommons.org/licenses/by/4.0/). Background. This randomised, double-blinded, single-centre study prospectively investigated the impact of goal directed therapy and fluid optimization with crystalloids or colloids on perioperative complications in patients un- dergoing brain tumour surgery. Main aim of the study was to investigate the impact of fluid type on postoperative complications. Patients and methods. 80 patients were allocated into two equal groups to be optimised with either crystalloids (n = 40) or colloids (n = 40). Invasive hemodynamic monitoring was used to adjust and maintain mean arterial pressure and cerebral oxygenation within the baseline values (± 20%) and stroke volume variation (SVV) ≤ 10%. Postoperative complications from different organ systems were monitored during the first 15 days after surgery. Hospital stay was also recorded. Results. Crystalloid group received significantly more fluids (p = 0.003) and phenylephrine (p = 0.02) compared to colloid group. This did not have any significant impact on perioperative complications and hospital stay, since no dif- ferences between groups were observed. Conclusions. Either crystalloids or colloids could be used for fluid optimization in brain tumour surgery. If protocol- ised perioperative haemodynamic management is used, the type of fluid does not have significant impact on the outcome. Key words: brain tumour surgery; fluid optimization; haemodynamic management Introduction Proper intravenous fluid therapy has effect on perioperative care and long-term postoperative outcome. Perioperative fluid therapy, guided by flow based haemodynamic monitors, can improve outcome. Optimization of hemodynamic and oxy- gen delivery by using a goal-directed therapy (IV fluids and/or vasoactive infusions), guided by ob- jective monitoring, could be more personalised ap- proach.1-3 Recent studies showed that haemodynamic management should be tailored to the cardio- vascular physiology and the clinical situation of each individual patient, the so called personalised haemodynamic management.4 It improves out- come of the surgery (better wound healing, shorter hospital stay, less surgical site infections, cardio- vascular and pulmonary complications).5 It is unclear whether crystalloid or colloid fluids or a combination should be used for goal directed therapy to optimise patient outcome and what is the clinical impact of this technique.5-8 Brain oedema prevention and optimization of cerebral perfusion and oxygenation are main goals of anaesthetic technique during brain surgery.9,10 Radiol Oncol 2022; 56(4): 508-514. Markovic-Bozic J et al. / Crystalloids vs. colloids in brain tumour surgery 509 Optimal neuroprotective strategies include ap- propriate patient positioning, management of sys- temic and cerebral haemodynamic, maintenance of fluid, electrolyte and coagulation balance, and postoperative prevention and treatment of pain, postoperative nausea and vomiting.8,9 The optimal volume status during brain sur- gery is not known. There are two main dilemmas regarding fluids, the use of liberal or restrictive protocol and the type of fluid used. Fluid therapy may augment both cardiac output and cerebral blood flow. Fluid overload may result in poor neu- rological outcome, but it is still uncertain if fluid restriction is favourable or damaging to post-crani- otomy neurological outcome. There is also concern regarding possible negative impact of colloids on coagulation that can cause bleeding and worsen outcome perioperatively.10-12 Stroke volume variation (SVV) is one of the dy- namic haemodynamic parameters that predicts in- traoperative fluid responsiveness also in brain sur- gery.13,14 The goal is to maintain systemic and cere- bral haemodynamic variables (cardiac output, arte- rial blood pressure, cardiac rhythm, cerebral blood flow).8,9 In our previous study we showed that type of anaesthesia for brain surgery does not have im- pact on haemodynamic stability and the occurrence of postoperative complications.8 But the question arised if the type of fluid used for managing sys- temic and cerebral haemodynamic variables does have any impact on the postoperative outcome. Thus, we hypothesized that for prevention of postcraniotomy complications haemodynamic op- timization is more important than the type of fluid (crystalloid or colloid) used. Main aim of the study was to investigate the im- pact of fluid type on perioperative complications. The primary outcome measure was the impact of type and consumption of fluid on the incidence of perioperative complications. The secondary outcome measure was the im- pact of perioperative complications on the length of hospital stay and mortality. Patients and methods Prospective, randomised, double-blind, single- centre study, with two parallel group, was con- ducted at the University Medical Centre Ljubljana, Department of Anaesthesiology and Surgical Intensive Care and Department of Neurosurgery in years 2016−2018 (trial registry on 15/08/2017; number NCT03249298 at www.clinicaltrials.gov). The study was approved by the National Medical Ethics Committee of the Republic of Slovenia. All the procedures were performed in accordance with the declaration of Helsinki. The CONSORT recom- mendations for reporting randomized trials were followed. Written informed consent was obtained from all subjects participating in the trial. ASA (American Society of Anaesthesiologists) Class 1−3 high risk surgical patients from the Clinical department of neurosurgery were includ- ed in the study. Adult patients that underwent brain tumour surgery were included. Exclusion criteria were (a) unwillingness to give a written informed consent, (b) cardiac arrhythmia (c) hemodynamic unstablity or shock, (d) coagula- tion disorder and (e) underage. All patients were visited by a member of our team a day prior to surgery to seek an informed consent and to answer any question. Patients were able to freely withdraw from the trial. Using a computer-generated list, the patients were randomised into two groups by the fourth au- thor, not involved in patient care. The first author enrolled the patients and informed them about the participation in the study. In the operating room standard monitoring was instituted. An arterial catheter was placed in the radial artery for continuous blood pres- sure monitoring. Advanced pulse contour cardiac output monitoring using the EVA 1000/FloTrac device (Edwards Lifescience, CA, USA) and near infrared spectroscopy oximetry (NIRS) monitoring (Medtronic, MN, USA) were applied. Patients were premedicated (midazolam 7.5 mg po). Antibiotic prophylaxis with intravenous ce- fazolin 2 g in 100 ml of 0,9% NaCl was invariably used in all patients. Anaesthesia was induced with propofol 1−2 mg- kg-1 (Propoven, Fresenius Kabi AG, Bad Homburg, Germany). Before intubation all patients received remifentanil 0.5−1 μgkg-1 (Ultiva, GlaxoSmithKline) and rocuronium 0.6 mgkg-1 (Esmeron, MSD, NY, USA). Patients were intubated and mechanically ven- tilated (oxygen-air mixtures, I/E ratio 1:2, tidal vol- ume 8 mlkg-1). The goal was to reach normal val- ues of partial pressure of carbon dioxide in arterial blood (paCO2) and normal values of partial pres- sure of oxygen in arterial blood. Anaesthesia was maintained by continuous infusion of propofol 4−6 mgkg-1h-1. Remifentanil was adjusted according to the degree of surgical manipulation (0.1−2 μgkg- 1min-1) and was increased when mean arterial pres- sure and heart rate increased over 30% from base- Radiol Oncol 2022; 56(4): 508-514. Markovic-Bozic J et al. / Crystalloids vs. colloids in brain tumour surgery510 line. The depth of anaesthesia was measured with bispectral index (BIS) and maintained from 40 to 60. This is according to hospital policy, since total intravenous infusion was used in order to prevent intraoperative awareness. Haemodynamic management was followed by study protocol. Intraoperative basal fluid re- placement was realized with continuous infu- sion 2−4 mlkg-1h-1 of balanced crystalloid regimes (Sterofundin ISO, B. Braun Melsungen AG). Additional boluses of 250 ml fluid were given when stroke volume variation (SVV) measured by EVA 1000/FloTrac system rose above 10% (a sustained change during the previous 5 minutes) or in the case of a positive response to previous fluid challenge until normal SVV value. Colloid group (CO) received colloid solution (Voluven 130/0.4 6%; Fresenius Kabi AG, Bad Homburg, Germany) and crystalloid group (CR) balanced crystalloid (Sterofundin). If mean arterial pressure (MAP) or cerebral oxygenation (rSO2) after fluid boluses were still < 20% from the baseline values with normal SVV values, vasoactive drugs were given (ephedrine 5−10 mg (0.5% Ephedrine, UMC Ljubljana Pharmacy, Slovenia) or phenylephrine 50 μg (0.01%, UMC Ljubljana Pharmacy, Slovenia)) to maintain MAP and/or rSO2 ± 20% from the base- line values. Bradycardia (heart rate (HR) < 40min-1) was treated with atropine 0.5 mg. If MAP and/or HR increased over 30% from baseline, the infusion of remifentanil was increased by 0.1 μg kg-1min-1. Any adverse haemodynamic events (increase of MAP and/or HR over 30% from baseline) that did not respond to higher remifentanil infusion rate, were managed with urapidil or metoprolol, as appropriate. Blood loss was replaced with col- loids (CO group) or crystalloids (CR group) until a reduced PRBC transfusion trigger (haemoglobin level < 90 gl-1) was reached, which is desirable level for neurosurgical patients. Haemodynamic param- eters were recorded continuously in 5-min inter- vals (from induction to discharge from the postan- aesthesia care unit (PACU)). Blood samples were collected before surgery, at the end of the surgery and on the first postopera- tive day to compare lactate values, to detect early coagulopathy with rotational tromboelastometry (ROTEM) and to predict blood transfusion require- ments.15 During dura closing piritramide 0.1 mgkg-1 (Dipidolor, Janssen-Cillag GmbH, Neuss, Germany), metamizole 2.5 g (Analgin, Stada AG, Bad Vilbel, Germany) and ondansetron 4 mg were given to the patients. Propofol infusion was stopped at the last skin suture. Remifentanil infusion was stopped after the removal of the Mayfield head holder. Postoperatively intravenous infusion of pirit- ramide was started as patient-controlled analgesia (PCA). The definition of operation duration was the time from the application of the Mayfield head holder to its removal. Duration of anaesthesia was measured from induction to extubation. The time from anaesthetics cessation to tracheal extubation was also recorded. All the patients were extubated in the operating theatre and then transferred to the PACU, where they stayed for not more than 2 hours. Afterwards they were admitted to the Department of Neurosurgery intensive care unit (ICU). Standard postoperative monitoring gener- ally used in these procedures was implemented. Oxygen was administered via a Venturi mask and titrated to the lowest level needed to achieve arte- rial oxygen saturation greater than 96%. During the hospital stay the main investigator (JMB) vis- ited the patients daily to check the postoperative complications and the fluid loading. Measurements The following data were collected: demograph- ics, duration of surgery and anaesthesia, the con- sumption of intraoperative drugs, haemodynamic variables, fluid balance, and serum safety control markers (lactate, haemoglobin, coagulation status), the length of hospital stay and postoperative com- plications during 15 days after surgery. Postoperative complications were defined as any unintended changes in body function or well- being, such as hypertension (systolic blood pres- sure 30% higher than the baseline level), infection, pulmonary, neurological events, reoperation and death. Statistical analysis The appropriate sample size was calculated from our previous pilot study of two independent groups (20 patients optimised with colloids and 20 patients treated with standard non-optimised ap- proach) using a priori two-tailed t-test power anal- ysis. The difference in the mean colloid consump- tion between the groups was used for the effect size calculation and the sample size determination. For a significance level of 5% (α = 0.05) and a power of 90% (β = 0.1), the calculated minimum sample size was 36. To compensate for possible withdrawals, 40 patients were included in each group. Two pa- Radiol Oncol 2022; 56(4): 508-514. Markovic-Bozic J et al. / Crystalloids vs. colloids in brain tumour surgery 511 tients from each group were excluded for further analysis because of technical reasons (Figure 1). The two-tailed t-test with unequal variances or the Chi-square test were used to test the differenc- es in demographic data, duration of the procedure and anaesthesia, drug consumption, fluid balance, haemodynamic parameters, postoperative compli- cations and length of hospital stay. The means of continuous variables are present- ed, and categorical data are summarized as counts. A p-value of less than 0.05 was considered statisti- cally significant. Data were analysed by SPSS 13.0 software package (IBM Corp., Armonk, NY, USA). Results 80 patients, aged 18−80 years, ASA (American Society of Anaesthesiologists) Class 1−3 and GCS (Glasgow coma score) of 15, scheduled for brain tumour surgery, were included in the study, 40 in the CO group and 40 in CR group (Figure 1). There were sixty-nine primary operations and 7 reop- erations. No significant differences (p > 0.05) were found between the groups regarding their demo- graphics, ASA class, position during surgery, type of surgery and duration of the procedure or anaes- thesia (Table 1). During the surgery CR group received statisti- cally significant more fluids (1120 ml vs 653 ml; p = 0.003) and vasoactive drug phenylephrine (874 mcg vs. 210 mcg; p = 0.02) (Table 2). On the other hand, differences in fluid balance (total fluids, blood transfusion, fresh frozen plasma, blood loss, urine volume) and the levels of serum safety markers (lactate, haemoglobin) during and 24 hours after the surgery were not significant (p > 0.05) (Table 2). Rotational tromboelastometry was normal in all patients before and after the surgery, whereas 9 patients had pathological result during the sur- gery, with nonsignificant differences between the groups (p = 0.57) (Table 2). 15 days after the surgery no significant differ- ences were recorded in the variables that could have influence on the outcome. 46 patients did not have any additional diseases or organ failure (including renal failure) in comparison with pre- operative condition (23 in each group; p = 0.41). In CR group one patient died and one had wound infection. In CO group one patient had systemic in- flammation and two pulmonary embolism. In both groups minor neurological complications were re- corded (13 vs. 12). The length of hospital stay was 9 days in both groups (p = 0.7). FIGURE 1. Flow diagram of the study. TABLE 1. Baseline demographics and surgical procedure Group CR (N = 38) CO (N = 38) p value Age (years) 54 ± 14 55 ± 16 0.69 Weight (kg) 79 ± 16 76 ± 15 0.45 Gender (M/F) 17/21 14/24 0.32 ASA (I/II/III) First operation/reoperation Patient position Supine Lateral Sitting Prone Localization Supratentorial/infratentorial Type of surgery Craniotomy/endoscopic Duration of procedure (min) Duration of anaesthesia (min) 8/19/11 33/5 24 13 1 0 33/5 35/3 195 ± 60 242 ± 64 7/24/7 36/2 22 12 2 2 33/5 37/1 209 ± 101 247 ± 105 0.46 0.43 0.48 0.63 0.50 0.49 0.82 The results are expressed as mean ± SD or number of patients. The differences between groups were not significant (p > 0.05). ASA = American Society of Anaesthesiologists; CO = colloid group; CR = crystalloid group; F = female; M = male Radiol Oncol 2022; 56(4): 508-514. Markovic-Bozic J et al. / Crystalloids vs. colloids in brain tumour surgery512 Discussion Historically anaesthesiologists observed patients and act according to clinical changes. If decision to give fluid bolus or vasoactive drugs is based only on low blood pressure, one could easily overlook the need for fluid and give just vasoactive drugs TABLE 2. Intraoperative and postoperative variables and outcome Group Intraoperative data CR CO P Propofol (mg) 1355 ± 451 1307 ± 766 0.74 Remifentanil (mg) 15 ± 8 13 ± 8 0.25 Total loss of blood (ml) Urine volume (ml) Total fluids (ml) 311 ± 262 996 ± 510 2250 ± 1000 461 ± 486 772 ± 655 2122 ± 758 0.09 0.99 0.53 Blood transfusion (ml) Fresh frozen plasma (ml) Fluid optimization boluses (1/2/3/>3 times) Consumption of optimization fluid (ml) 17 ± 107 13 ± 78 5/6/2/14 1120 ± 816 73 ± 203 61 ± 185 8/13/6/9 653 ± 365 0.14 0.14 0.16 0.003* Intraoperative hypotension (1/2/3/>3 times) 9/7/6/8 6/7/3/6 0.88 Vasoactive drugs (1/2/3/>3 times/infusion) Phenylephrine (mcg) Ephedrine (mg) 6/4/4//3/11 874 ± 1632 8 ± 10 6/5/1/5/5 210 ± 530 7 ± 13 0.41 0.02* 0.64 Urapidil (mg) 3 ± 10 3 ± 8 0.88 Metoprolol (mg) Atropine (mg) Tromboelastometry (normal/ pathological) 0.13 ± 0.8 0.07 ± 0.2 33/5 0.13 ± 0.8 0.08 ± 0.2 33/4 1 0.7 0.57 Lactate (mmol/l) Haemoglobin (g/l) Postoperative data (24 h) Arterial pressure (normal/low/high) 1.1 ± 0.4 120±13 37/1/0 0.88 ± 0.5 115 ± 12 34/0/4 0.1 0.1 0.08 Postoperative CT of the head (good/ oedema/haematoma/other) Total fluids (ml) Urine volume (ml) 30/6/1/1 1693 ± 520 1382 ± 660 28/6/4/0 1772 ± 684 1297 ± 735 0.41 0.57 0.59 Lactate (mmol/l) Haemoglobin (g/l) 1.1 ± 0.4 123 ± 17 0.95 ± 0.4 119 ± 13 0.25 0.29 Postoperative data (15 days) No difference (comparing to data before surgery) Death 23 1 23 0 0.41 Wound infection 1 0 Inflammation 0 1 Pulmonary (pneumonia/embolism) Neurological complications (minor/ major) Hospital stay (days) 0/0 13/0 9 ± 4 0/2 12/0 9 ± 5 0.70 The results are expressed as mean ± SD or number of patients; The differences between groups that are significant are labelled with * (p<0.05) CO = colloid group; CR = crystalloid group and vice versa. Namely, liberal fluid approach can prolong hospital stay and lead to oedema, on the other hand restrictive fluid regime is correlated with postoperative complications.16-19 That is ex- tremely important in neurosurgery, where infusing too much fluid can result in brain oedema and hy- poperfusion. Invasive haemodynamic monitoring is therefore important to control brain perfusion. According to the results of Luo and co- workers goal directed fluid therapy significantly reduces the consumption of colloids and crystalloids com- pared to the group, where therapeutic decisions were left at the discretion of the attending anesthe- siologist and intensivist.20 Feldheiser and colleagues showed that colloids have longer intravenous effect and enable better haemodynamic stability and flow measurement.5 This can explain why in our study the crystalloid group received more phenylephrine. Our first goal was to achieve the desired SVV with fluid optimisation. Vasoactive drugs were used only if hypotension persisted.21 Hypotension occurred more often in crystalloid group, but non- significant. These patients needed more fluid, and even when optimised, they still needed fenilefrin to achieve desired perfusion pressure. This was the reason why crystalloid group needed more phe- nylephrine, even though number of fenilefrin in- terventions did not vary between the groups. Lactate is a measurement of adequate tissue perfusion and was not significantly raised in our groups. Wu and co-workers showed that for su- pratentorial brain tumor resection, fluid boluses targeting lower SVV are more beneficial than a restrictive protocol, and result in lower lactate, brain biomarkers and postoperative neurological events.22 The incidence of intraoperative events that need- ed intervention (fluid and/or vasoactive drugs) did not differ between our groups. Intraoperative sta- bile patients did not need any intervention with fluid bolus or vasoactive drugs for haemodynamic optimisation. Optimal brain perfusion prevents brain ischemia and oedema in patient undergoing neurosurgical procedure. Haemostasis is also essential to prevent worse outcome caused with haematoma. Colloids could have impact on coagulation. It was shown by Lindroos and colleagues that HES induced a slight disturbance in fibrin formation and clot strength.23 We used ROTEM to exclude possible side effects of colloids on haemostasis. We also showed that fluid optimisation with crystalloids is safe. Even though their consump- Radiol Oncol 2022; 56(4): 508-514. Markovic-Bozic J et al. / Crystalloids vs. colloids in brain tumour surgery 513 tion was larger compared to colloids. The amount of colloids needed for optimisation was 41% lower, which was less then described in the literature.23,24 Obviously, good outcome with no postoperative neurological complications in both our groups showed that technique and haemodynamic man- agement are more important than the type and vol- ume of fluid. Namely, cognitive functions such as attention, concentration and memory can also be transient affected due to temporary brain swell- ing.25 Xia and co-workers showed that goal-direct- ed colloid therapy was not superior to goal-direct- ed cristalloid therapy for brain relaxation, cerebral oxygenation or cerebral metabolism, although less fluid was needed to maintain the target SVV in the colloid group.26 Fluids and vasoactive drugs should be applied according to haemodynamic measure- ments.4 Every patient should receive as much fluid as needed at appropriate time.27 Conclusions Our study showed that either crystalloids or col- loids could be used for fluid optimization for brain tumour surgery. If protocolised periopera- tive haemodynamic management is used, the type of fluid does not have significant impact on out- come. Future studies in this area should focus on the development of broad goal directed strategies in perioperative fluid therapy rather than trying to find the best type of fluid. Acknowledgments We are thankful to Department of Anaesthesiology and Surgical Therapy, University Medical Centre Ljubljana, Slovenia which supported the research and to all colleagues, anaesthesiologists, surgeons and nurses at the Department of Anaesthesiology and Surgical Therapy and at the Department of Neurosurgery who in any way helped in this work. We are also thankful to all the patients who cooper- ated in the study. References 1. Manning MW, Dunkman WJ, Miller TE. Perioperative fluid and hemody- namic management within an enhanced recovery pathway. J Surg Oncol 2017; 116: 592-600. doi: 10.1002/jso.24828 2. Žličar M. Current concepts in fluid therapy and non-invasive haemodynamic monitoring. Signa Vitae 2017; 13: 53-5. doi: 10.22514/SV131.032017.7 3. Saugel B, Cecconi M, Wagner JY, Reuter DA. Noninvasive continuous cardiac output monitoring in perioperative and intensive care medicine. Br J Anaest 2015; 114: 562-75. doi: 10.1093/bja/aeu447 4. Saugel B, Vincent JL. Protocolised personalised peri-operative haemody- namic management. Eur J Anaesthesiol 2019; 36: 551-4. doi: 10.1097/ EJA.0000000000001015 5. Feldheiser A, Pavlova V, Bonomo T, Jones A, Fotopoulou C, Sehouli J, et al. Balanced crystalloid compared with balanced colloid solution using goal- directed haemodynamic algorithm. Br J Anaesth 2013; 110: 231-40. doi: 10.1093/bja/aes377 6. Yates DRA, Davies SJ, Milner HE, Wilson RJT. Crystalloid or colloid for goal- directed fluid therapy in colorectal surgery. Br J Anaesth 2014; 112: 281-9. doi: 10.1093/bja/aet307 7. Doherty M, Buggy DJ. Intraoperative fluids: how much is too much? Br J Anaesth 2012; 109: 69-79. doi: 10.1093/bja/aes171 8. Markovič-Božič J, Karpe B, Potočnik I, Jerin A, Vranič A, Novak-Jankovič V. Effect of propofol and sevoflurane on the inflammatory response of pa- tients undergoing craniotomy. BMC Anesthesiol 2016; 16: 18. doi: 10.1186/ s12871-016-0182-5 9. El Beheiry H. Protecting the brain during neurosurgical procedures: strate- gies that can work. Curr Opin Anaesthesiol 2012; 25: 548-55. doi: 10.1097/ ACO.0b013e3283579622 10. Wu CY, Lin YS, Tseng HM, Cheng HL, Lee TS, Lin PL, et al. Comparison of two stroke volume variation-based goal-directed fluid therapies for supratento- rial brain tumour resection: randomized controlled trial. Br J Anaesth 2017; 119: 934-42. doi: 10.1093/bja/aex189 11. Xia J, He Z, Cao X, Che X, Chen L, Zhang J, et al. The brain relaxation and cerebral metabolism in stroke volume variation-directed fluid therapy during supratentorial tumors resection: crystalloid solution versus col- loid solution. J Neurosurg Anesthesiol 2014; 26: 320-7. doi: 10.1097/ ANA.0000000000000046 12. Tommasino C. Fluid management. In: Newfield P, Cottrell JE, editors. Handbook of Neuroanaesthesia. 4 th Edition. New York: Lippincott-Williams & Wilkins; 2007. 379-95. 13. Benes J, Haidingerova L, Pouska J, Stepanik J, Stenglova A, Zatloukal J, et al. Fluid management guided by a continuous non-invasive arterial pressure device is associated with decreased postoperative morbidity after total knee and hip replacement. BMC Anesthesiol 2015; 15: 148. doi: 10.1186/ s12871-015-0131-8 14. Saugel B, Reuter DA. Are we ready for the age of non-invasive haemody- namic monitoring? Br J Anaesth 2014; 113: 340-3. doi: 10.1093/bja/aeu145 15. Ellenberger C, Garofano N, Barcelos G, Diaper J, Pavlovic G, Licker M. Assessment of haemostasis in patients undergoing emergent neurosurgery by rotational elastometry and standard coagulation tests: a prospective observational study. BMC Anesthesiol 2017; 17: 146. doi: 10.1186/s12871- 017-0440-1 16. Thacker JKM, Mountford WK, Ernst FR, Krukas MR, Mythen MMG. Perioperative fluid utilization variability and association with outcomes. Considerations for enhanced recovery efforts in sample US surgical popula- tions. Ann Surg 2016; 263: 502-10. doi: 10.1097/SLA.0000000000001402 17. Giglio MT, Marucci M, Testini M, Brienza N. Goal-directed haemodynamic therapy and gastrointestinal complications in major surgery: a meta-anal- ysis of randomized controlled trials. Br J Anaesth 2009; 103: 637-46. doi: 10.1093/bja/aep279 18. Grocott MPW. The Cochrane database of systematic reviews 2012–2014. John Wiley & Sons, Ltd.; 2006. doi: 10.1002/14651858.CD004082.pub2 19. Grocott MPW, Dushianthan A, Hamilton MA, Mythen MG, Harrison D, Rowan K. Perioperative increase in global blood flow to explicit defined goals and outcomes after surgery: a Cochrane systematic review. Br J Anaesth 2013; 111: 535-48. doi: 10.1093/bja/aet155 20. Luo J, Xue J, Liu J, Liu B, Liu L, Chen G. Goal-directed fluid restriction during brain surgery: a prospective randomized controlled trial. Ann Intensive Care 2017; 7: 16. doi: 10.1186/s13613-017-0239-8 21. Berkenstadt H, Margalit N, Hadani M, Z Friedman, E Segal, Y Villa, et al. Stroke volume variation as a predictor of fluid responsiveness in patients undergoing brain surgery. Anesth Analg 2001; 92: 984-9. doi: 10.1097/00000539-200104000-00034 Radiol Oncol 2022; 56(4): 508-514. Markovic-Bozic J et al. / Crystalloids vs. colloids in brain tumour surgery514 22. Wu CY, Lin YC, Tsend HM, Cheng HL, Lee TS, Lin PL, et al. Comparison of two stroke volume variation-based goal-directed fluid therapies for supratento- rial brain tumour resection: a randomized controlled trial. Br J Anaesth 2017; 119: 934-42. doi: 10.1093/bja/aex189 23. Lindroos AC, Niiya T, Randell T, Niemi TT. Stroke volume-directed adminis- tration of hydroxyethyl starch (HES 130/0.4) and Ringer’s acetate in prone position during neurosurgery: a randomized controlled trial. J Anesth 2014; 28: 189-97. doi: 10.1007/s00540-013-1711-8 24. Lindroos AC, Niiya T, Silvasti-Lundell M, Randell T, Hernesniemi J, Niemi TT. Stroke volume-directed administration of hydroxyethyl starch or Ringer’s acetate in sitting position during craniotomy. Acta Anaesthesiol Scand 2013; 57: 729-36. doi: 10.1111/aas.12105 25. Kos N, Kos B, Benedicic M. Early medical rehabilitation after neurosurgical treatment of malignant brain tumours in Slovenia. Radiol Oncol 2016; 50: 139-44. doi: 10.1515/raon-2015-0004 26. Xia J, He Z, Cao X, Che X, Chen L, Zhang J, et al. The brain relaxation and cerebral metabolism in stroke volume variation – directed fluid therapy during supratentorial tumors resection: crystalloid solution versus col- loid solution. J Neurosurg Anesthesiol 2014; 26: 320-27. doi: 10.1097/ ANA.0000000000000046 27. Kirov, MY, Kuzkov VV, Molnar Z. Perioperative haemodynamic therapy. Curr Opin Crit Care 2010; 16: 384-92. doi: 10.1097/MCC.0b013e32833ab81e